How Many People Use BPC-157? The 2026 Numbers

BPC-157, the pentadecapeptide nicknamed the “Wolverine peptide” for its muscle-recovery reputation, has one of the widest gaps in peptide research between animal evidence and human data. As of late August 2026, the molecule has more than a hundred preclinical studies behind it — and still no published, peer-reviewed human efficacy data. That gap is starting to close, slowly, with at least one actively recruiting human trial.

Real-world use (Sept 15, 2026)

New, confirmed BPC-157 users rose 33-fold between 2020 and 2026, according to a real-world analysis of medical records by the data-analytics firm nference — the first quantified answer to how many people are using the peptide, and one published alongside analysts’ estimate that BPC-157 and other peptides could quickly become a $2 billion to $3 billion market if legitimized. That market figure is an analyst estimate quoted by Reuters, not a measured number, and the growth curve is narrower than it looks: it counts newly documented users in one data network, published ahead of peer review, and the study leader says the actual scale of use is unknown.

Reuters reported the findings on September 15, 2026 (Nancy Lapid). The analysis itself was posted on Preprints.org on September 7, 2026 and carries the posting’s own flag, verbatim: “This version is not peer-reviewed.” All eight authors are employees of nference, which ran the work on its own federated data network; the paper declares no external funding.

Why the count had to be built from clinical notes

BPC-157 has no approved product, so it has no National Drug Code and no structured prescription record. Reuters’ wording is that real-world use “is hard to track using electronic health records because it lacks a National Drug Code”, so exposure had to be derived from the free text of clinicians’ notes. Reuters describes the screening as nference reviewing “more than 15 million medical records” and identifying 1,039 patients whose doctors had manually documented use of the peptide in written clinical notes. The paper’s own count is 15.2 million patients in the federated network with at least one clinical note between 2020 and 2026, of whom 1,536 (0.01%) had a note mentioning BPC-157; model-assisted curation then confirmed administration for 1,039 of those, or 67.6%. That 1,039 is the analytic cohort — a documentation count, not a count of US users.

The study leader’s own framing is why the number reads as a floor rather than a total. Venky Soundararajan: “Most likely, very few doctors are even asking their patients, ‘Are you taking BPC-157?’”

The shape of the cohort

Source: nference analysis (preprint DOI 10.20944/preprints202609.0501.v1), figures as reported by Reuters, September 15, 2026.

The demographic skew is as quotable as the trend. Among the 972 users with recorded race, 95.9% were white — the Reuters copy rounds this to 96% — against 78% of the background care population in the same network, a 1.23-fold enrichment rather than anything that describes BPC-157 users in general. Across all years rather than the year-by-year split, the cohort is 59.5% male with a mean age of 49.6.

What people used it for, and where they got it

Reasons for use were documented for 644 patients: pain (33% of all 1,039 users), gastrointestinal conditions including reflux, inflammatory bowel disease or gastritis (14%), prior injury (11% — the category Reuters paraphrases as “sports injuries”) and post-surgical healing (10%). Reuters’ own summary sentence is that the compound was “most often initiated to help manage pain or gastrointestinal symptoms”.

Sourcing was documented for only 205 of the 1,039 users (19.7%), and it reads as a two-track market: compounding pharmacies (74 of 205, 36%) and gray-market peptide vendors (71 of 205, 35%). That is the paper’s own answer to where BPC-157 comes from, and it is the same split the market data measures from the buyer’s side — see our gray-market peptide lab-testing report and the black-market dose-accuracy testing it pairs with, while the compounding half of that split is what the compounding pharmacy checklist walks through.

What the analysis cannot show

Directional outcomes were recorded for 354 of the 1,039 users (34.1%); response direction was unavailable for the other 685 (65.9%). Among the 354 with a recorded direction, 279 (79%) improved, 16% showed no change and 5% were recorded as worse. Reuters’ summary is that responses to treatment “were only recorded for one-third of the patients in the study”.

Among the 129 patients with documented discontinuation, the most common reason was advice from a clinician (59 of 129, 46%), followed by adverse effects (24 of 129, 19%) and perceived ineffectiveness (21 of 129, 16%) — the paper’s support for Reuters’ line that when patients stopped, “it was most often because their doctors advised them to stop”. Documented adverse events were infrequent and the paper flags them as under-counted: neuropsychiatric (1.4%), injection-site hypersensitivity (1.4%) and gastrointestinal (1.3%) events, described in the paper as “infrequently noted and likely subject to under-reporting”. Reuters’ summary of the same material lists neuropsychiatric, dermatologic and gastrointestinal symptoms.

The caveat that governs every number above. Dr. Flynn McGuire of the University of Utah, who has researched BPC-157 but was not involved in the analysis, noted that about half of the patients with documented use — 525 of 1,039 (50.5%) — were taking other drugs as well, most commonly testosterone (17.0%), NSAIDs (14.7%), TB-500 (12.9%) and corticosteroids (11.7%), plus non-drug interventions including physical therapy (15.3%) and surgery (12.6%). His point is not a detail to file away: “There was no placebo or untreated comparator, and there was no standardized indication, formulation, dose, route, treatment duration, or outcome assessment.” Therefore, “it’s impossible to know how much of any improvement was attributable to BPC-157 versus natural recovery, other treatments, placebo effects, or selective documentation,” McGuire and the paper’s authors emphasized — randomized controlled trials are needed to answer whether BPC-157 actually causes clinically meaningful improvement. The paper states the identical limit in its own words: “These reports cannot establish efficacy or distinguish BPC-157 effects from peptide stacking, other co-treatments, non-drug interventions, placebo effects or selection, reporting and confirmation biases.” Nothing in this dataset shows that BPC-157 works.

Where the regulatory position stands

BPC-157 “has not been approved for use in the United States”. In July 2026, a panel of FDA advisers voted to allow pharmacy compounding of BPC-157, encouraged by Health Secretary Robert F. Kennedy Jr., after the FDA had restricted compounding of the peptide over what it said were significant safety risks and insufficient human data. The FDA’s own framing of that July 23-24 meeting is narrower than “approval”: the committee was weighing whether to include BPC-157-related bulk drug substances on the 503A Bulks List, its recommendations are non-binding, and agency staff had recommended against adding the peptide — citing “insufficient clinical safety information to characterize the safety profile of BPC-157” and the absence of any studies administering it to humans by the proposed routes. The vote tally is not published in the meeting materials or in the wire copy, so this page does not state one. Our PCAC tracker follows that docket, and the compound’s status, evidence base and sourcing are covered in the BPC-157 guide.

The Clinical Trial That Is Actually Running

The most concrete human development is NCT07437547, a randomized, double-blind, placebo-controlled Phase 2 study of BPC-157 for acute grade II hamstring strains, registered on ClinicalTrials.gov in February 2026. The trial is designed to measure both structural healing and functional recovery — endpoints that go beyond the anecdotal self-reports that dominate online BPC-157 discussion.

What makes the trial notable is not just that it exists, but what it signals: a shift from decades of rat models toward the kind of controlled human study design that regulators and insurers actually rely on. It remains a single, early-phase trial — it does not make BPC-157 an approved treatment, and a positive result in one muscle-injury indication would not generalize to the broad “recovery peptide” claims common in marketing.

Where the Human Evidence Stands

The strongest prior human data point cited in 2026 reviews remains a Phase 2 trial in inflammatory bowel disease, which showed dose-dependent improvement in ulcerative colitis symptoms. That study is frequently mentioned in BPC-157 clinical trial overviews as the most cited human evidence, but reviewers consistently note its small scale and the absence of replication.

An August 2026 industry review of the BPC-157 clinical research landscape describes renewed interest from academic and commercial sponsors, and early regulatory conversations with the FDA. “After decades of promising preclinical research, BPC-157 is attracting renewed clinical interest in 2026, with academic and commercial sponsors initiating human trials,” the review states — while cautioning that human data remains preliminary.

The Animal Evidence Base

The preclinical record is extensive. More than 100 animal studies have examined BPC-157 across tendon healing, ligament repair, gastrointestinal protection, and angiogenesis. The compound was first described as a fragment of human gastric juice in the 1990s — a finding that has been questioned by researchers who have been unable to replicate it, including Stanford’s Katrin Svensson, PhD, in the Stanford Medicine peptide explainer we covered in August.

The consistent theme in the 2026 trial-status guides is that animal promise has not yet translated into the human evidence that would satisfy a regulator. Enthusiasts often treat “studied in animals for decades” as proof of safety; researchers treat it as a reason to run the human trials that would settle the question.

Why the Human Data Gap Matters

The distinction matters for anyone following BPC-157 for one reason: every claim about the peptide in the consumer market outruns the human evidence. Preclinical success does not predict clinical safety or efficacy — the history of drug development is full of compounds that looked excellent in animal models and failed or proved toxic in humans. That is why the FDA requires controlled human trials before approval, and why no compounding or research product containing BPC-157 is an approved treatment for any condition.

The July 2026 Pharmacy Compounding Advisory Committee vote to recommend BPC-157 for the 503A bulks list — tracked in our PCAC tracker — is a compounding-process decision, not a safety or efficacy endorsement.

What to Watch

The milestones that would actually move the needle: whether NCT07437547 completes enrollment and reports results; whether any sponsor files an IND; and whether a second independent human trial appears. Those are the events that would narrow the gap between the peptide’s reputation and its evidence. Until then, the honest summary of BPC-157 in 2026 is unchanged: promising in animals, unproven in humans, and — for the research-community audience tracking the field — worth watching rather than worth concluding from.

Frequently asked questions: BPC-157 users and statistics

How many people use BPC-157?

The best available count is 1,039 people, and it is a floor rather than a total: nference screened the records of 15.2 million patients and found 1,039 whose clinicians had written BPC-157 into their clinical notes — a figure Reuters reported on September 15, 2026.

Is BPC-157 legal to compound?

Compounding is the lawful route to BPC-157 in the United States as of September 15, 2026: the FDA removed the peptide from Category 2 on April 15, 2026, and in July 2026 an FDA advisory panel voted to recommend it for the 503A compounding list, a recommendation that is not binding and leaves formal rulemaking pending.

Do the 2026 BPC-157 user statistics show it works?

No: an outcome was recorded for only 354 of the 1,039 clinician-documented users (34.1%), and the analysis carried no placebo, comparator, standardized dose or outcome measure, so Reuters reported that it cannot show whether BPC-157 caused any improvement.

How many people use the Wolverine stack of BPC-157 and TB-500?

In the nference analysis Reuters reported on September 15, 2026, 12.9% of the 1,039 clinician-documented BPC-157 users were also recorded as taking TB-500 — the other half of the BPC-157-plus-TB-500 pairing known as the Wolverine stack — the only published co-use figure for that combination.

Those two halves and what the human evidence says for each are set out in our looksmaxxing peptide review, and the TB-500 compound guide covers the second peptide’s own evidence base and sourcing position.

Sources

1. Reuters: “Use of untested Wolverine peptide backed by US health secretary Kennedy on the rise, study finds” — Nancy Lapid, September 15, 2026. Reuters blocks non-browser requests; the wire text used here was read from the syndicated copy at Yahoo News.
2. nference analysis of real-world BPC-157 use — DOI 10.20944/preprints202609.0501.v1, Preprints.org (MDPI AG), submitted September 5, 2026, posted September 7, 2026. The posting’s own flag: “This version is not peer-reviewed.”
3. FDA Pharmacy Compounding Advisory Committee, July 23-24, 2026 meeting.
4. FDA briefing document: Evaluation of BPC-157-related bulk drug substances.

All sources checked September 15, 2026.

Nothing in this article is medical advice. BPC-157 is an experimental compound intended for laboratory research, not an approved treatment for any condition.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.